SPL Medical has entered into an Agreement with NanoEcho for supply and application of Ferrotran® (Ferumoxtran) for Ul-trasound detection of Lymph node metastases.

Nijmegen, The Netherlands, 27.02.2024 - The business agreement, signed today by SPL Medical and NanoEcho, is a comprehensive contract. The agreement grants NanoEcho exclusivity regarding the supply of ferumoxtran (iron oxide-based nanoparticles) for use in magnetomotive ultrasound.

For the clinical effectiveness of the NanoEcho system, the choice of nanoparticles is of crucial im-portance. Ferumoxtran is chosen based on its unique ability to spread in the lymphatic system and differentiate between diseased and healthy tissue in lymph node metastasis. NanoEcho has evaluated the unique lymphotropic capabilities in animal studies and the results form the basis for the choice for this particle. They support and underline the efficacy data of SPL medical. The agreement includes downpayments and purchase commitments for both the planned clinical study and future commercial sales.

In NanoEcho's method for functional diagnostics of rectal cancer lymph node metastases, modern ultrasound technology is used together with iron-oxide nanoparticles. For the clinical effectiveness of the system, the choice of the appropriate nanoparticle is essential.
Ferrotran®, the lymphotropic nanoparticle of SPL medical, is in advanced phase III for the detec-tion of lymph node metastases for prostate cancer patients with Magnetic Resonance Imaging (MRI).
The Ferrotran® particle has been developed as a platform technology for various applications for the broad base of installed MRI scanners worldwide. With this collaboration with NanoEcho the Ferrotran® platform technology will be extended also to modern ultrasound technologies.

We are very pleased with the outcome of this agreement and the exceptional professionalism demonstrated by SPL Medical. This agreement is of utmost significance for our business and rep-resents a significant milestone for us at NanoEcho. We look forward to continuing to work with full focus on market approval of our system and are very pleased with this significant step for-ward," says Linda Persson, CEO of NanoEcho.

"The extension of the scope of applicability of Ferrotran® to ultrasound technology demonstrates the unique power of our platform technology beyond the broad field of nanoparticle-MRI. By the cooperation with NanoEcho, SPL medical can further extend the applicability of Ferrotran® to the benefit of an enhanced patient population in a critical oncological status", says Dr. Jürgen Feuer-stein CEO for SPL Medical.

Toernooiveld 100
6525 EC Nijmegen
The Netherlands
For more information about Ferrotran®, the clinical trials or SPL Medical: Dr. Juergen Feuerstein (CEO) at +49 171 173 5476

About Ferrotran®:
Ferrotran® belongs to the group of USPIO's (Ultrasmall Superparamagnetic Particles of Iron Ox-ide). Ferrotran® can be applied in MRI as a safe bloodpool agent for angiography and for func-tional diagnostics in detection of even the smallest lymph node metastases in prostate cancer patients and is currently under investigation for use in various other cancers.
Ferrotran® is safe, as it is based on iron and therefore metabolized naturally in the body.
Ferrotran® is in advanced phase III in various prestigious European University Hospitals. Ferro-tran® has been applied successfully in over 700 patients in the Netherlands and Switzerland in special approval permissions.

About SPL Medical:
SPL medical is a spin-off of the Radboud university medical center and is funded additionally by Oost NL, a Dutch regional venture capital company, and b.e.imaging GmbH, a German company specialized in the development and commercialization of contrast agents.

This release was published on openPR.